Developing two novel drugs to improving the lives of people with neurodevelopmental disabilities, with potential for first US marketing approval in Q1 2023.
View our Annual Reports
View Investor Presentations, Audio, Video
Visit our Shareholder Services
View Latest Investor Presentation
